Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.42 |
| ▸ | MPL | P40238 | 2/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13601588 | 0.89 | AKR1C3 (0.50) | TAS2R14MYCSCN9AAKR1C3AKR1C2 | |
| SCHEMBL13601673 | 0.88 | TAS2R14 (0.41) | TAS2R14MYCSCN9ASORT1AKR1C3 | |
| SCHEMBL13601650 | 0.84 | DHODH (0.47) | MYCDHODHNOTUM | |
| SCHEMBL13601657 | 0.82 | MYC (0.42) | TAS2R14MYCSCN9ADHODHMRGPRX4 | |
| SCHEMBL13601649 | 0.80 | RORC (0.49) | MPLAKR1C3AKR1C2GPBAR1GRIN2B | |
| SCHEMBL13601647 | 0.78 | ACMSD (0.50) | MYCDHODHNOTUM | |
| SCHEMBL30532289 | 0.76 | TAS2R14 (0.46) | TAS2R14SCN9ASORT1AKR1C3AKR1C2 | |
| SCHEMBL28570642 | 0.76 | TAS2R14 (0.46) | TAS2R14SCN9ASORT1AKR1C3AKR1C2 | |
| SCHEMBL13601645 | 0.75 | FABP4 (0.52) | MYCSCN9ADHODH | |
| SCHEMBL13601631 | 0.73 | LDHA (0.49) | MYCSCN9AAKR1C3AKR1C2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298894-A1 | AMINO ACID COMPOUNDS | S1PR1, S1PR2, S1PR5 | TAS2R14 4160/4885MPL 217/4885MYC 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.